Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Blood. 2021 May 13;137(19):2704-2707. doi: 10.1182/blood.2020008119.

Christopher R Bolen¹, Federico Mattiello², Michael Herold³, Wolfgang Hiddemann⁴, Sarah Huet^{5

6

7}, Wolfram Klapper⁸, Robert Marcus⁹, Farheen Mir¹⁰, Gilles Salles^{5

11}, Oliver Weigert^{12

13

14}, Tina Nielsen², Mikkel Z Oestergaard¹⁵, Jeffrey M Venstrom¹⁶

¹ Bioinformatics & Computational Biology, Genentech Inc., South San Francisco, CA.
² Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
³ HELIOS-Klinikum Erfurt, Erfurt, Germany.
⁴ Department of Medicine III, University Hospital, LMU Munich, Germany.
⁵ Equipe Labellisée Ligue Contre le Cancer, Cancer Research Centre of Lyon, Oullins, France.
⁶ Laboratoire d'Hématologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
⁷ Faculté de Pharmacie de Lyon, Université Claude Bernard Lyon-1, Lyon, France.
⁸ Institute of Pathology, University Medical Center Schleswig-Holstein, Kiel, Germany.
⁹ HCA Healthcare, London, United Kingdom.
¹⁰ Royal Marsden Hospital, Sutton, United Kingdom.
¹¹ Service d'Hématologie Clinique, Hospices Civils de Lyon et Université Claude Bernard Lyon-1, Pierre-Benite, France.
¹² Department of Internal Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research, University Hospital of the Ludwig-Maximilians-University, Munich, Germany.
¹³ German Cancer Consortium, Heidelberg, Germany.
¹⁴ German Cancer Research Centre, Heidelberg, Germany.
¹⁵ Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and.
¹⁶ Department of Clinical Development, Foundation Medicine, Cambridge, MA.

No abstract available

Publication types